Shield Therapeutics has agreed to take full commercial control of its oral iron therapy ACCRUFeR in the US from Viatris starting September 30, without any upfront payment. Instead, Shield will pay reduced royalties on US sales over five years. This move is seen as a major strategic step to improve profit margins by internalizing the sales team, despite higher operating costs. Broker Cavendish maintains a buy rating and forecasts Shield's revenue to rise to £78.7 million in 2026, up from £49.7 million in 2025, signaling strong growth potential.
Seagate Technology reported a 34% revenue increase and $3.1 billion free cash flow in fiscal 2026, driven by high demand for large-capacity hard drives from hyperscalers supporting AI infrastructure. The company beat earnings estimates for four conse...
Jim Cramer warns that political opposition and stricter regulations could slow the rapid expansion of data centers, impacting valuations of companies benefiting from the AI infrastructure boom. While smaller developers may struggle with new rules, la...
